Your search history is turned on.
Date: May 3, 2024 Jurisdictions: All jurisdictions
printmgr file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 Zymeworks Inc. (Exact name of registrant as specified in its charter) ...
printmgr file Filed Pursuant to Rule 424(b)(5) Registration No. 333-279073 PROSPECTUS SUPPLEMENT (To Prospectus dated May 2, 2024) Up to 570,637 Shares Common Stock We are registering the issuance, from time to time, of up to 570,637 shares of common stock issuable upon the exchange of exchangeable shares, or the Exchangeable S...
printmgr file Filed Pursuant to Rule 424(b)(5) Registration No. 333-279073 PROSPECTUS SUPPLEMENT (To Prospectus dated May 2, 2024) Zymeworks Inc. Up to $150,000,000 Common Stock We have previously entered into a sales agreement, or Sales Agreement, with Cantor Fitzgerald & Co., or Cantor, dated as of November 9, 2022, relating to th...
Date: May 2, 2024 Jurisdictions: All jurisdictions
ZYME-2024.03.31-Ex 31.2-2024-05-02-10-04 Exhibit 31.2 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kenneth Galbraith, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Zymeworks Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fa...
ZYME-2024.03.31-Ex 31.1-2024-05-02-10-04 Exhibit 31.1 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kenneth Galbraith, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Zymeworks Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fa...
printmgr file As filed with the Securities and Exchange Commission on May 2, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZYMEWORKS INC. (Exact name of registrant as specified in its charter) ...
ZYME-2024.03.31-10Q Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations. The following discussion should be read in conjunction with the attached financial statements and notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q, as well as our audited financial statements and related notes thereto and m...
1. 10Q_Q1'24-2024-05-02-10-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or TRANSITION ...
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027 Completion of rolling biologics license application (BLA) filing with the U.S. Food and Drug Administration (FDA) for zanidatamab ...
Date: April 30, 2024 Jurisdictions: All jurisdictions
Zymeworks Announces Participation in Upcoming Investor Conferences VANCOUVER, British Columbia, April 30, 2024 -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conf...